Expert Review of Anticancer Therapy,
Год журнала:
2025,
Номер
unknown
Опубликована: Апрель 12, 2025
Bone
metastasis
often
develops
in
advanced
malignancies.
Lipid
metabolic
dysregulation
might
play
pivotal
role
cancer
progression
and
subsequent
deterioration
of
bone
health
at
metastatic
condition.
In-depth
understanding
lipid
reprogramming
metastasized
cells
other
stromal
including
marrow
adipocyte
(BMA)
is
an
urgent
need
to
develop
effective
therapy.
This
paper
emphasizes
providing
overview
multifaceted
dysregulated
lipids
BMA
association
with
by
utilizing
search
terms
metabolism,
PubMed.
study
extends
address
mechanism
linked
metabolism
various
crucial
genes
(e.g.
CSF-1,
RANKL,
NFkB
NFATc1)
involved
metastasis.
review
examines
therapeutic
strategies
targeting
offer
potential
avenues
disrupt
lipid-driven
On
condition,
molecules
especially
not
only
favors
but
also
potentiate
within
cells.
Distinct
lipid-metabolism
associated
may
act
as
biomarker,
these
challenging
task
for
specific
treatment.
Curbing
function
resorption
controlling
drugs
statins,
omega-3
FA
metformin)
provide
additional
support
curtail
lipid-associated
Journal of Hematology & Oncology,
Год журнала:
2024,
Номер
17(1)
Опубликована: Апрель 2, 2024
Abstract
Cancer
immunotherapy
and
vaccine
development
have
significantly
improved
the
fight
against
cancers.
Despite
these
advancements,
challenges
remain,
particularly
in
clinical
delivery
of
immunomodulatory
compounds.
The
tumor
microenvironment
(TME),
comprising
macrophages,
fibroblasts,
immune
cells,
plays
a
crucial
role
response
modulation.
Nanoparticles,
engineered
to
reshape
TME,
shown
promising
results
enhancing
by
facilitating
targeted
These
nanoparticles
can
suppress
fibroblast
activation,
promote
M1
macrophage
polarization,
aid
dendritic
cell
maturation,
encourage
T
infiltration.
Biomimetic
further
enhance
increasing
internalization
agents
cells
such
as
cells.
Moreover,
exosomes,
whether
naturally
secreted
body
or
bioengineered,
been
explored
regulate
TME
immune-related
affect
cancer
immunotherapy.
Stimuli-responsive
nanocarriers,
activated
pH,
redox,
light
conditions,
exhibit
potential
accelerate
co-application
with
checkpoint
inhibitors
is
an
emerging
strategy
boost
anti-tumor
immunity.
With
their
ability
induce
long-term
immunity,
nanoarchitectures
are
structures
development.
This
review
underscores
critical
overcoming
current
driving
advancement
modification.
Experimental Hematology and Oncology,
Год журнала:
2024,
Номер
13(1)
Опубликована: Янв. 29, 2024
Abstract
Metabolic
reprogramming
is
an
emerging
hallmark
of
cancer
cells,
enabling
them
to
meet
increased
nutrient
and
energy
demands
while
withstanding
the
challenging
microenvironment.
Cancer
cells
can
switch
their
metabolic
pathways,
allowing
adapt
different
microenvironments
therapeutic
interventions.
This
refers
heterogeneity,
in
which
cell
populations
use
pathways
sustain
survival
proliferation
impact
response
conventional
therapies.
Thus,
targeting
heterogeneity
represents
innovative
avenue
with
potential
overcome
treatment
resistance
improve
outcomes.
review
discusses
patterns
developmental
stages,
summarizes
molecular
mechanisms
involved
intricate
interactions
within
metabolism,
highlights
clinical
vulnerabilities
as
a
promising
regimen.
We
aim
unravel
complex
characteristics
develop
personalized
approaches
address
distinct
traits,
ultimately
enhancing
patient
Metabolic
alterations,
a
hallmark
of
cancer,
enable
tumor
cells
to
adapt
their
environment
by
modulating
glucose,
lipid,
and
amino
acid
metabolism,
which
fuels
rapid
growth
contributes
treatment
resistance.
In
primary
breast
metabolic
shifts
such
as
the
Warburg
effect
enhanced
lipid
synthesis
are
closely
linked
chemotherapy
failure.
Similarly,
metastatic
lesions
often
display
distinct
profiles
that
not
only
sustain
but
also
confer
resistance
targeted
therapies
immunotherapies.
The
review
emphasizes
two
major
aspects:
mechanisms
driving
in
both
how
unique
environments
sites
further
complicate
treatment.
By
targeting
vulnerabilities
at
stages,
new
strategies
could
improve
efficacy
existing
provide
better
outcomes
for
cancer
patients.
JCO Oncology Practice,
Год журнала:
2025,
Номер
unknown
Опубликована: Янв. 7, 2025
PURPOSE
The
prognostic
significance
of
concomitant
statin
use
in
cancer
treatment
with
immune
checkpoint
inhibitors
(ICIs)
remains
a
subject
ongoing
investigation.
This
study
aims
to
clarify
the
value
this
patient
population
and
provide
robust,
evidence-based
foundation
guide
therapeutic
decisions.
METHODS
A
systematic
search
strategy
was
used
across
multitude
digital
archives
exhaustively
identify
all
relevant
academic
literature
published
up
until
June
20,
2024.
Studies
English
that
reported
hazard
ratios
(HRs)
for
overall
survival
(OS)
and/or
progression-free
(PFS),
along
corresponding
95%
CIs,
were
considered
eligible
inclusion.
Meta-analyses
conducted
calculate
combined
HRs
CIs.
RESULTS
total
25
studies,
involving
46,154
patients
cancer,
included
meta-analysis.
pooled
results
indicated
linked
better
OS
(HR,
0.80
[95%
CI,
0.71
0.92])
PFS
0.69
under
ICI
therapy.
Sensitivity
analyses
further
validated
consistency
robustness
results.
CONCLUSION
On
basis
available
clinical
evidence,
is
an
improved
prognosis
oncology
on
ICI-based
These
observations
underscore
potential
as
important
adjunctive
therapy
paradigm
ICI-treated
thereby
establishing
their
key
consideration
management
strategies.
Further
randomized
controlled
trials
are
imperative
validate
effect
within
realm
Molecular Aspects of Medicine,
Год журнала:
2025,
Номер
101, С. 101335 - 101335
Опубликована: Янв. 1, 2025
Renal
cell
carcinoma
(RCC)
is
a
malignant
tumor
with
highly
heterogeneous
and
complex
molecular
mechanisms.
Through
systematic
analysis
of
TCGA,
COSMIC
other
databases,
24
mutated
genes
closely
related
to
RCC
were
screened,
including
VHL,
PBRM1,
BAP1
SETD2,
which
play
key
roles
in
signaling
pathway
transduction,
chromatin
remodeling
DNA
repair.
The
PI3K/AKT/mTOR
particularly
important
the
pathogenesis
RCC.
Mutations
such
as
PIK3CA,
MTOR
PTEN
are
associated
metabolic
abnormalities
proliferation.
Clinically,
mTOR
inhibitors
VEGF-targeted
drugs
have
shown
significant
efficacy
personalized
therapy.
Abnormal
regulation
reprogramming,
especially
glycolysis
glutamine
pathways,
provides
cells
continuous
energy
supply
survival
advantages,
GLS1
promising
results
preclinical
studies.
This
paper
also
explores
potential
immune
checkpoint
combination
targeted
drugs,
well
application
nanotechnology
drug
delivery
In
addition,
unique
mechanisms
revealed
individualized
therapeutic
strategies
explored
for
specific
subtypes
TFE3,
TFEB
rearrangement
type
SDHB
mutant
type.
review
summarizes
common
gene
mutations
their
mechanisms,
emphasizes
diagnosis,
treatment
prognosis,
looks
forward
prospects
multi-pathway
therapy,
immunotherapy
treatment,
providing
theoretical
support
clinical
guidance
new
development.
Biochimica et Biophysica Acta (BBA) - Reviews on Cancer,
Год журнала:
2025,
Номер
unknown, С. 189259 - 189259
Опубликована: Янв. 1, 2025
As
immunosuppressive
cells,
Regulatory
T
cells
(Tregs)
exert
their
influence
on
tumor
immune
escape
within
the
microenvironment
(TME)
by
effectively
suppressing
activity
of
other
thereby
significantly
impeding
anti-tumor
response.
In
recent
years,
metabolic
characteristics
Tregs
have
become
a
focus
research,
especially
important
role
lipid
metabolism
in
maintaining
function
Tregs.
Consequently,
targeted
interventions
aimed
at
modulating
been
recognized
as
an
innovative
and
promising
approach
to
enhance
effectiveness
immunotherapy.
This
review
presents
comprehensive
overview
pivotal
regulating
Tregs,
with
specific
targeting
augment
responses.
Furthermore,
we
discuss
potential
opportunities
challenges
associated
this
strategy,
aiming
provide
novel
insights
for
enhancing
efficacy
cancer
Frontiers in Immunology,
Год журнала:
2023,
Номер
14
Опубликована: Ноя. 14, 2023
Tumor-associated
macrophages
(TAMs)
are
integral
to
the
tumor
microenvironment
(TME),
influencing
cancer
progression
significantly.
Attracted
by
cell
signals,
TAMs
exhibit
unparalleled
adaptability,
aligning
with
dynamic
milieu.
Their
roles
span
from
promoting
growth
and
angiogenesis
modulating
metastasis.
While
substantial
research
has
explored
fundamentals
of
TAMs,
comprehending
their
adaptive
behavior,
leveraging
it
for
novel
treatments
remains
challenging.
This
review
delves
into
TAM
polarization,
metabolic
shifts,
complex
orchestration
cytokines
chemokines
determining
functions.
We
highlight
complexities
TAM-targeted
focusing
on
adaptability
potential
variability
in
therapeutic
outcomes.
Moreover,
we
discuss
synergy
integrating
TAM-focused
strategies
established
treatments,
such
as
chemotherapy,
immunotherapy.
Emphasis
is
laid
pioneering
methods
like
reprogramming
immunotherapy
adoption
single-cell
technologies
precision
intervention.
synthesis
seeks
shed
light
TAMs’
multifaceted
cancer,
pinpointing
prospective
pathways
transformative
enhancing
modalities
oncology.
Lipids in Health and Disease,
Год журнала:
2024,
Номер
23(1)
Опубликована: Фев. 1, 2024
Abstract
Lipid
metabolism
in
cancer
cells
has
garnered
increasing
attention
recent
decades.
Cancer
thrive
hypoxic
conditions,
nutrient
deficiency,
and
oxidative
stress
cannot
be
separated
from
alterations
lipid
metabolism.
Therefore,
exhibit
increased
metabolism,
uptake,
lipogenesis
storage
to
adapt
a
progressively
challenging
environment,
which
contribute
their
rapid
growth.
Lipids
aid
cell
activation.
absorb
lipids
with
the
help
of
transporter
translocase
proteins
obtain
energy.
Abnormal
levels
series
synthases
over-accumulation
tumor
microenvironment
(TME).
reprogramming
plays
an
essential
role
TME.
are
closely
linked
several
immune
phenotypic
transformation.
The
further
promotes
immunosuppression,
leads
escape.
This
event
significantly
affects
progression,
treatment,
recurrence,
metastasis
cancer.
present
review
describes
TME
examines
connection
between
immunotherapy.
